Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Epirubicin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP2A known ✓ | P11388 | 5/20 | 1.00 |
| ▸ | MEN1 | O00255 | 9/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 9/20 | 1.00 |
| ▸ | THRB | P10828 | 8/20 | 1.00 |
| ▸ | BLM | P54132 | 8/20 | 1.00 |
| ▸ | RECQL | P46063 | 7/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 6/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 6/20 | 1.00 |
| ▸ | BRCA1 | P38398 | 6/20 | 1.00 |
| ▸ | MAPT | P10636 | 6/20 | 1.00 |
| ▸ | S100A4 | P26447 | 6/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 4/20 | 1.00 |
| ▸ | USP2 | O75604 | 4/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 4/20 | 1.00 |
| ▸ | STAT6 | P42226 | 4/20 | 1.00 |
| ▸ | PAX8 | Q06710 | 4/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 1.00 |
| ▸ | ABCB1 | P08183 | 3/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Doxorubicin SCHEMBL317301 | 1.00 | MEN1 (1.00) | MEN1KMT2ATHRBBLMRECQL | |
| Epirubicin SCHEMBL9335136 | 1.00 | MEN1 (1.00) | MEN1KMT2ATHRBBLMRECQL | |
| Epirubicin SCHEMBL6251124 | 1.00 | MEN1 (1.00) | MEN1KMT2ATHRBBLMRECQL | |
| Doxorubicin SCHEMBL3242 | 1.00 | MEN1 (1.00) | MEN1KMT2ATHRBBLMRECQL | |
| Epirubicin SCHEMBL317302 | 1.00 | MEN1 (1.00) | MEN1KMT2ATHRBBLMRECQL | |
| Epirubicin SCHEMBL6423994 | 1.00 | MEN1 (1.00) | MEN1KMT2ATHRBBLMRECQL | |
| Doxorubicin SCHEMBL57097 | 1.00 | MEN1 (1.00) | MEN1KMT2ATHRBBLMRECQL | |
| Epirubicin SCHEMBL21669731 | 1.00 | MEN1 (1.00) | MEN1KMT2ATHRBBLMRECQL | |
| Epirubicin SCHEMBL21669733 | 1.00 | MEN1 (1.00) | MEN1KMT2ATHRBBLMRECQL | |
| Doxorubicin SCHEMBL5324652 | 1.00 | MEN1 (1.00) | MEN1KMT2ATHRBBLMRECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050118600-A1 | Method for selecting drug sensitivity-determining factors and method for predicting drug sensitivity using the selected factors | F. HOFFMANN-LA ROCHE AG (CH) | 2005-06-02 | — | — | US | claimed |
| EP-1492523-A2 | METHOD FOR IDENTIFICATION OF TUMOR TARGETING ENZYMES | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2005-01-05 | — | — | EP | claimed |
| US-20030138864-A1 | Method for identifying an enzyme to design anti-cancer compounds | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2003-07-24 | — | — | US | claimed |
| WO-2003043631-A2 | METHOD FOR IDENTIFICATION OF TUMOR TARGETING ENZYMES | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2003-05-30 | — | — | WO | claimed |
| US-20240148740-A1 | COMBINATION OF AN AHR INHIBITOR WITH A PDX INHIBITOR OR DOXORUBICINE | PAHR THERAPEUTICS, INC. | 2024-05-09 | — | — | US | disclosed |
| EP-3517526-B1 | PYRIDINONES AS REARRANGED DURING TRANSFECTION (RET) INHIBITORS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2020-08-19 | — | — | EP | disclosed |
| US-10709695-B2 | Compounds as rearranged during transfection (RET) inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2020-07-14 | — | — | US | disclosed |
| EP-3191449-B1 | COMPOUNDS AS REARRANGED DURING TRANSFECTION (RET) INHIBITORS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2020-07-01 | — | — | EP | disclosed |
| EP-3670539-A1 | MATERIAL AND METHODS FOR TREATING OR PREVENTING HER-3 ASSOCIATED DISEASES | Daiichi Sankyo Europe GmbH (DE) | 2020-06-24 | — | — | EP | disclosed |
| EP-3351558-B1 | MATERIAL AND METHODS FOR TREATING OR PREVENTING HER-3 ASSOCIATED DISEASES | DAIICHI SANKYO EUROPE GMBH (DE) | 2020-03-11 | — | — | EP | disclosed |
| US-20190247382-A1 | NOVEL COMPOUNDS AS REARRANGED DURING TRANSFECTION (RET) INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-08-15 | — | — | US | disclosed |
| EP-3517526-A1 | NOVEL COMPOUNDS AS REARRANGED DURING TRANSFECTION (RET) INHIBITORS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2019-07-31 | — | — | EP | disclosed |
| US-20100113392-A1 | METHODS OF USING SAHA AND BORTEZOMIB FOR TREATING MULTIPLE MYELOMA | MERCK SHARP & DOHME CORP. | 2010-05-06 | — | — | US | disclosed |
| US-20090247549-A1 | Methods of using saha and bortezomib for treating cancer | SCHERING CORPORATION | 2009-10-01 | — | — | US | disclosed |
| US-20090105329-A1 | Methods of Treating Cancers with SAHA, Carboplatin, and Paclitaxel and Other Combination Therapies | NATIONAL INSTITUTES OF HEALTH (DEITR) | 2009-04-23 | — | — | US | disclosed |
| US-20080269182-A1 | Method of treating cancers with SAHA and Pemetrexed | PLUDA JAMES | 2008-10-30 | — | — | US | disclosed |
| US-20070197473-A1 | Methods of using SAHA and Bortezomib for treating cancer | MERCK & CO., INC. | 2007-08-23 | — | — | US | disclosed |
| US-20070117815-A1 | Method of treating cancers with SAHA and pemetrexed | MERCK & CO., INC. | 2007-05-24 | — | — | US | disclosed |
| US-20050118600-A1 | Method for selecting drug sensitivity-determining factors and method for predicting drug sensitivity using the selected factors | F. HOFFMANN-LA ROCHE AG (CH) | 2005-06-02 | — | — | US | disclosed |
| US-20030138864-A1 | Method for identifying an enzyme to design anti-cancer compounds | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2003-07-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090247549-A1 | Methods of using saha and bortezomib for treating cancer | HDAC5, HDAC6, HDAC4 | TOP2A 236/4885MEN1 3151/4885KMT2A 152/4885 |
| US-20070197473-A1 | Methods of using SAHA and Bortezomib for treating cancer | HDAC5, HDAC6, HDAC4 | TOP2A 236/4885MEN1 3151/4885KMT2A 152/4885 |
| US-20030138864-A1 | Method for identifying an enzyme to design anti-cancer compounds | RNASE1, GUSB, DPEP1 | TOP2A 590/4885MEN1 3082/4885KMT2A 2754/4885 |
| US-20070117815-A1 | Method of treating cancers with SAHA and pemetrexed | HDAC5, HDAC1, HDAC4 | TOP2A 44/4885MEN1 1486/4885KMT2A 60/4885 |
| US-20240148740-A1 | COMBINATION OF AN AHR INHIBITOR WITH A PDX INHIBITOR OR DOXORUBICINE | AHR, ARNT, AIPL1 | TOP2A 869/4885MEN1 4798/4885KMT2A 104/4885 |
| US-20090105329-A1 | Methods of Treating Cancers with SAHA, Carboplatin, and Paclitaxel and Other Combination Therapies | HDAC5, HDAC1, HDAC6 | TOP2A 81/4885MEN1 2736/4885KMT2A 102/4885 |
| US-20100113392-A1 | METHODS OF USING SAHA AND BORTEZOMIB FOR TREATING MULTIPLE MYELOMA | HDAC5, HDAC4, HDAC6 | TOP2A 494/4885MEN1 1215/4885KMT2A 39/4885 |
| US-20190247382-A1 | NOVEL COMPOUNDS AS REARRANGED DURING TRANSFECTION (RET) INHIBITORS | RET, FER, THRB | TOP2A 4691/4885MEN1 188/4885KMT2A 2386/4885 |
| US-20080269182-A1 | Method of treating cancers with SAHA and Pemetrexed | HDAC5, HDAC1, HDAC4 | TOP2A 44/4885MEN1 1486/4885KMT2A 60/4885 |
| US-10709695-B2 | Compounds as rearranged during transfection (RET) inhibitors | RET, FER, THRB | TOP2A 4577/4885MEN1 187/4885KMT2A 2276/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.